Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  ACS Chemical Neuroscience

• Publication date

  2018-01-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acschemneuro.7b00439PMID 29244487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stabilizing amyloid-β peptide by the N-terminus capture is capable of preventing and eliminating amyloid-β oligomers.

  2017cited by this paper
• Polymer-Peptide Conjugates Disassemble Amyloid β Fibrils in a Molecular-Weight Dependent Manner.

  2017cited by this paper
• Inhibition and Degradation of Amyloid Beta (Aβ40) Fibrillation by Designed Small Peptide: A Combined Spectroscopy, Microscopy, and Cell Toxicity Study.

  2017cited by this paper
• N-Terminally Truncated Amyloid-β(11-40/42) Cofibrillizes with its Full-Length Counterpart: Implications for Alzheimer's Disease.

  2017cited by this paper
• Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.

  2016cited by this paper
• Synergistic Inhibitory Effect of Peptide-Organic Coassemblies on Amyloid Aggregation.

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Graphene quantum dots for the inhibition of β amyloid aggregation.

  2015cited by this paper
• Graphene quantum dot hybrids as efficient metal-free electrocatalyst for the oxygen reduction reaction.

  2013cited by this paper
• Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment.

  2012cited by this paper
• In vivo NIR fluorescence imaging, biodistribution, and toxicology of photoluminescent carbon dots produced from carbon nanotubes and graphite.

  2012cited by this paper
• Resolving controversies on the path to Alzheimer's therapeutics

  2011cited by this paper
• Strongly green-photoluminescent graphene quantum dots for bioimaging applications.

  2011cited by this paper
• Hydrothermal Route for Cutting Graphene Sheets into Blue‐Luminescent Graphene Quantum Dots

  2010cited by this paper
• Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

  2010cited by this paper
• Amino Acid Position-specific Contributions to Amyloid β-Protein Oligomerization*

  2009cited by this paper
• Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

  2009cited by this paper
• Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.

  2009cited by this paper
• Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway.

  2009cited by this paper
• Animal models of Alzheimer's disease and frontotemporal dementia

  2008cited by this paper
• Role of the region 23-28 in Abeta fibril formation: insights from simulations of the monomers and dimers of Alzheimer's peptides Abeta40 and Abeta42.

  2008cited by this paper
• Structure and dynamics of the Abeta(21-30) peptide from the interplay of NMR experiments and molecular simulations.

  2008cited by this paper
• Amyloid Fibrils of the HET-s(218–289) Prion Form a β Solenoid with a Triangular Hydrophobic Core

  2008cited by this paper
• Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.

  2008cited by this paper
• C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity

  2008cited by this paper
• Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation

  2008cited by this paper
• Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

  2008cited by this paper
• Molecular basis for passive immunotherapy of Alzheimer's disease

  2007cited by this paper
• Alzhemed: a potential treatment for Alzheimer's disease.

  2007cited by this paper
• Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid

  2007cited by this paper
• β-Sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange

  2007cited by this paper
• Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate.

  2007cited by this paper
• Insight Into the Kinetic of Amyloid β (1–42) Peptide Self‐Aggregation: Elucidation of Inhibitors’ Mechanism of Action

  2007cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Congo red and protein aggregation in neurodegenerative diseases.

  2007cited by this paper
• A century-old debate on protein aggregation and neurodegeneration enters the clinic

  2006cited by this paper
• Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13.

  2006cited by this paper
• Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model

  2006cited by this paper
• A Century of Alzheimer's Disease

  2006cited by this paper
• Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils.

  2005cited by this paper
• Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo*

  2005cited by this paper
• The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation

  2005cited by this paper
• Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation

  2004cited by this paper
• Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation

  2004cited by this paper
• Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

  2002cited by this paper
• Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF.

  2001cited by this paper
• Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

  1999cited by this paper
• β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

  1998cited by this paper
• Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red.

  1997cited by this paper
• Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease.

  1994cited by this paper
• Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution

  1993cited by this paper

• Carboxylated graphene quantum dots inhibit Aβ42 and α-synuclein co-aggregation via competitive N-terminal targeting: An REMD study

  2026cites this paper
• In silico investigation of CNS-11 as a potential inhibitor of Aβ42 aggregation and its protofibril disassembly.

  2025cites this paper
• Carbon dots meet artificial intelligence: applications in biomedical engineering.

  2025cites this paper
• Biological applications of graphene-based nanomaterials in neurodegenerative diseases

  2025influential citation
• Unveiling Polyphyllin's Role in Neuroprotection: A Pharmacological Perspective

  2025cites this paper
• Development and Assessment of Polyacrylamide-Starch Hydrogel Nanocomposites with Graphene Quantum Dots for Targeted Quercetin Delivery to Brain Tumors

  2025cites this paper
• Anti-neurodegenerative potential of polyphyllin: Mechanisms involving inflammation and oxidative stress modulation

  2025cites this paper
• ALZ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study

  2025cites this paper
• Carbon-based nanomaterials: interactions with cells, brain therapies, and neural sensing

  2025cites this paper
• Advances in Deep Brain Imaging with Quantum Dots: Structural, Functional, and Disease-Specific Roles

  2024cites this paper
• Surface-engineered quantum dot nanocomposites for neurodegenerative disorder remediation and avenue for neuroimaging

  2024cites this paper
• Application of carbon dots-based nanomaterials in amyloid aggregation disease

  2024cites this paper
• Advancements of carbon dots: From the perspective of medicinal chemistry.

  2024cites this paper
• Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach

  2023cites this paper
• Co-biopolymer of chitosan/carboxymethyl cellulose hydrogel improved by zinc oxide and graphene quantum dots nanoparticles as pH-sensitive nanocomposite for quercetin delivery to brain cancer treatment.

  2023cites this paper
• Therapeutic Potential of Nanomedicine in Management of Alzheimer’s Disease and Glioma

  2023cites this paper
• Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays

  2023cites this paper
• N, F-doped graphene quantum dots effectively inhibit the fibrillization of amyloid-beta peptide (1–42)

  2023cites this paper
• Applications of Carbon Dots for the Treatment of Alzheimer’s Disease

  2022cites this paper
• Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases

  2022cites this paper
• Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease

  2022cites this paper
• Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation

  2022cites this paper
• Self-Therapeutic Nanomaterials: Applications in Biology and Medicine.

  2022cites this paper
• Detection and modulation of neurodegenerative processes using graphene-based nanomaterials: Nanoarchitectonics and applications.

  2022cites this paper
• Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease.

  2022cites this paper
• Graphene Quantum Dots: A Pharmaceutical Review

  2022cites this paper
• Graphene quantum dots obstruct the membrane axis of Alzheimer's amyloid beta.

  2021cites this paper
• Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's β-Amyloid.

  2021cites this paper
• Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration

  2021cites this paper
• Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature

  2021cites this paper
• A Ratiometric Fluorescent Conjugated Oligomer for Amyloid β Recognition, Aggregation Inhibition, and Detoxification.

  2021cites this paper
• Quantum dot: Heralding a brighter future in neurodegenerative disorders

  2021cites this paper
• Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.

  2021cites this paper
• Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends

  2021cites this paper
• Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

  2021cites this paper
• Carbon Dots: A Future Blood–Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier

  2021cites this paper
• Biomaterials

  2020cites this paper
• Electrochemistry and Electrocatalysis of Hemoglobin Based on Graphene Quantum Dots Modified Electrode

  2020cites this paper
• Bleomycin modulates amyloid aggregation in β-amyloid and hIAPP

  2020cites this paper
• The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases

  2020cites this paper
• Inhibition and disaggregation of amyloid β protein fibrils through conjugated polymer-core thermoresponsive micelles.

  2020cites this paper
• Nitrogen-Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer's β-Amyloid Plaques.

  2020cites this paper
• Amyloidosis Inhibition, a New Frontier of the Protein Corona.

  2020cites this paper
• Nanomaterial synthesis, an enabler of amyloidosis inhibition against human diseases.

  2020cites this paper
• Nontoxic Black Phosphorus Quantum Dots Inhibit Insulin Amyloid Fibrillation at an Ultralow Concentration

  2020cites this paper
• Graphene quantum dots redefine nanobiomedicine.

  2020cites this paper
• Neurotheranostics as personalized medicines.

  2019cites this paper
• Quantum dots as promising theranostic tools against amyloidosis: A review.

  2019cites this paper
• Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?

  2019cites this paper
• Black Phosphorus Nanomaterials Regulate the Aggregation of Amyloid‐β

  2019cites this paper
• Modulation of β-amyloid aggregation by graphene quantum dots

  2019cites this paper
• Genistein: A Dual Inhibitor of Both Amyloid β and Human Islet Amylin Peptides.

  2018cites this paper